» Articles » PMID: 38142739

Translation of Cell Therapies to Treat Autoimmune Disorders

Overview
Specialty Pharmacology
Date 2023 Dec 24
PMID 38142739
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune diseases are a diverse and complex set of chronic disorders with a substantial impact on patient quality of life and a significant global healthcare burden. Current approaches to autoimmune disease treatment comprise broadly acting immunosuppressive drugs that lack disease specificity, possess limited efficacy, and confer undesirable side effects. Additionally, there are limited treatments available to restore organs and tissues damaged during the course of autoimmune disease progression. Cell therapies are an emergent area of therapeutics with the potential to address both autoimmune disease immune dysfunction as well as autoimmune disease-damaged tissue and organ systems. In this review, we discuss the pathogenesis of common autoimmune disorders and the state-of-the-art in cell therapy approaches to (1) regenerate or replace autoimmune disease-damaged tissue and (2) eliminate pathological immune responses in autoimmunity. Finally, we discuss critical considerations for the translation of cell products to the clinic.

References
1.
Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View

2.
Hogrebe N, Maxwell K, Augsornworawat P, Millman J . Generation of insulin-producing pancreatic β cells from multiple human stem cell lines. Nat Protoc. 2021; 16(9):4109-4143. PMC: 8529911. DOI: 10.1038/s41596-021-00560-y. View

3.
van Vollenhoven R, Ernestam S, Geborek P, Petersson I, Coster L, Waltbrand E . Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009; 374(9688):459-66. DOI: 10.1016/S0140-6736(09)60944-2. View

4.
Drujont L, Carretero-Iglesia L, Bouchet-Delbos L, Beriou G, Merieau E, Hill M . Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection. PLoS One. 2014; 9(6):e100013. PMC: 4057339. DOI: 10.1371/journal.pone.0100013. View

5.
Al-Toma A, Visser O, van Roessel H, von Blomberg B, Verbeek W, Scholten P . Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood. 2006; 109(5):2243-9. DOI: 10.1182/blood-2006-08-042820. View